Cite
HARVARD Citation
Ferron‐Brady, G. et al. (2021). Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma. Clinical pharmacology & therapeutics. 110 (5), pp. 1282-1292. [Online].